HC Wainwright Has Negative Forecast for MIST Q3 Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 EPS estimate for Milestone Pharmaceuticals to ($0.14) from a previous estimate of ($0.10), while maintaining a "Buy" rating with a target price of $5.00.
• Milestone Pharmaceuticals missed analysts' consensus with reported Q2 earnings of ($0.20) EPS against an estimate of ($0.18) EPS.
• Institutional investors hold 86.18% of Milestone Pharmaceuticals' stock, with notable increases in positions from firms like Creative Planning and XTX Topco Ltd.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.14) per share for the quarter, down from their previous forecast of ($0.10). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.66) EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at $0.02 EPS and FY2029 earnings at $0.23 EPS.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST traded down $0.0350 during mid-day trading on Friday, hitting $1.6350. 596,072 shares of the company's stock traded hands, compared to its average volume of 1,731,442. The firm has a 50 day moving average of $1.71 and a two-hundred day moving average of $1.59. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The firm has a market capitalization of $87.41 million, a price-to-earnings ratio of -1.95 and a beta of 0.52. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 4.06.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning increased its stake in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company's stock valued at $45,000 after acquiring an additional 10,000 shares during the period. Raymond James Financial Inc. raised its stake in shares of Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company's stock valued at $84,000 after acquiring an additional 10,000 shares during the last quarter. Bay Rivers Group bought a new position in shares of Milestone Pharmaceuticals in the second quarter valued at approximately $28,000. XTX Topco Ltd grew its stake in shares of Milestone Pharmaceuticals by 52.7% during the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock valued at $42,000 after purchasing an additional 17,950 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after purchasing an additional 30,772 shares during the last quarter. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.